Inventiva Beheer

Beheer criteriumcontroles 2/4

De CEO Inventiva is Frederic Cren, benoemd in Jan2011, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt € 1.00M, bestaande uit 30.4% salaris en 69.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.45% van de aandelen van het bedrijf, ter waarde € 13.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.2 jaar en 7.8 jaar.

Belangrijke informatie

Frederic Cren

Algemeen directeur

€1.0m

Totale compensatie

Percentage CEO-salaris	30.4%
Dienstverband CEO	13.8yrs
Eigendom CEO	6.4%
Management gemiddelde ambtstermijn	8.2yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Frederic Cren's beloning veranderd ten opzichte van Inventiva's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

Compensatie versus markt: De totale vergoeding ($USD 1.06M ) Frederic } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 793.15K ).

Compensatie versus inkomsten: De vergoeding van Frederic is gestegen terwijl het bedrijf verliesgevend is.

CEO

Frederic Cren (58 yo)

13.8yrs

Tenure

€1,003,699

Compensatie

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.6m
Jean Volatier	Deputy GM & CFO	12.3yrs	geen gegevens	0.17% € 368.5k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	geen gegevens	0.017% € 36.9k
Eric Duranson	General Counsel	3.3yrs	geen gegevens	0.017% € 36.9k
Nathalie Harroy	Head of Human Resources	12.8yrs	geen gegevens	0.075% € 161.6k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	geen gegevens	geen gegevens
Michael Cooreman	Chief Medical Officer	4.1yrs	geen gegevens	0.017% € 36.9k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	geen gegevens	0.0086% € 18.4k

8.2yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6IVA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.8m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.6m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	geen gegevens
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	geen gegevens
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	geen gegevens
Sven Francque	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Manal Abdelmalek	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kenneth Cusi	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Glen Clack	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gérard Zalcman	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens

7.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6IVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Inventiva Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd